Form 4: Royalty Pharma CFO Sells Shares Under Pre-Arranged 10b5-1 Plan

Royalty Pharma's EVP & CFO, Terrance P. Coyne, sold 34,791 Class A Ordinary Shares on March 23, 2026, for a weighted average price of $45.5287 per share under a pre-arranged 10b5-1 plan.

Summary

• Terrance P. Coyne, EVP & CFO of Royalty Pharma plc (RPRX), reported the sale of Class A Ordinary Shares.
• A total of 34,791 Class A Ordinary Shares were sold on March 23, 2026.
• The sales were executed at a weighted average price of $45.5287 per share, with individual transactions ranging from $45.30 to $45.94.
• These transactions were conducted pursuant to a Rule 10b5-1 plan adopted by Mr. Coyne on August 8, 2025.
• Following these transactions, Mr. Coyne beneficially owns 160,108 Class A Ordinary Shares directly and indirectly.
• Additionally, Mr. Coyne and family vehicles hold limited partnership interests exchangeable into 6,448,180 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd (RPH) exchangeable into 1,807,277 Class A Ordinary Shares, subject to vesting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as neutral. While it's an insider sale, the execution under a pre-arranged 10b5-1 plan indicates a planned liquidity event rather than a reaction to new information, thus mitigating any negative signal.

Negatives

• An executive officer, Terrance P. Coyne, sold a significant number of Class A Ordinary Shares (34,791 shares).
• While executed under a 10b5-1 plan, insider sales can sometimes be perceived negatively by the market, indicating a reduction in management's direct equity exposure.

Risks

• Potential for negative market perception regarding insider selling, even if pre-planned, which could put minor downward pressure on the stock.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales, particularly by high-ranking executives, are routinely monitored by investors for insights into management's perception of future company performance. However, sales executed under a Rule 10b5-1 plan, as in this case, are pre-scheduled and typically do not signal a change in management's outlook or a lack of confidence in the company's prospects. Such plans are often established for personal financial planning and diversification.

Corporate Governance

Related Party Transactions

• Indirect beneficial ownership through TPC RP 2021, LLC and TPC RP EPA1 LLC.
• Indirect beneficial ownership through Spouse's IRA and Spouse.
• Holdings in RPI US Partners 2019, LP and Royalty Pharma Holdings Ltd (RPH) Class E Ordinary Shares, which are entities related to the Reporting Person's overall compensation and investment structure.

Stakeholder Impact

• Shareholders: May observe a minor increase in available shares on the market, but the impact is generally minimal due to the pre-planned nature of the sale.
• Employees: No direct impact.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Key Dates

Recommendation

The sale by Royalty Pharma's EVP & CFO, Terrance P. Coyne, was executed under a pre-arranged 10b5-1 plan, which indicates a scheduled liquidity event rather than a reaction to new material non-public information. Such transactions are generally considered neutral and do not typically provide a strong signal for a 'buy' or 'sell' recommendation based solely on this filing. Therefore, a 'hold' recommendation is appropriate as this event does not alter the fundamental investment thesis.

Keywords

Royalty Pharma, RPRX, Terrance P. Coyne, Form 4, insider trading, stock sale, 10b5-1 plan, executive compensation, beneficial ownership